Ropes & Gray represented Sarepta Therapeutics, Inc. in its credit and security agreement with Midcap Financial to establish a senior secured term loan facility that allows Sarepta to borrow up to $40 million at an annual rate of 7.75 percent, with a maturity of June 2018, subject to certain conditions and other applicable fees. The deal was announced June 29.
Sarepta is a biopharmaceutical company that makes ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and life-threatening diseases.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.